Research Use Only: This product is supplied for laboratory research and in-vitro studies. Not for human or veterinary administration.
Thymosin Alpha-1
- 28-Amino Acid Immunomodulator: N-terminal fragment of prothymosin alpha (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN), originally isolated from thymus 1977, 3,000+ publications, thymalfasin (Zadaxin) approved in 35+ countries
- Pleiotropic Immune Activation: TLR2/3/4/7/9 agonist, dendritic cell activation, T-cell maturation (CD4+/CD8+), Th1 polarization (IL-2/IL-12/IFN-γ↑), NK cell enhancement, PD-1/Tim-3 exhaustion marker reduction
- Clinical Status: FDA orphan drug (DiGeorge anomaly, melanoma, hepatitis B, HCC), China approved for hepatitis B/HCC, COVID-19 mortality reduction (11.11% vs 30.00%, Liu et al. 2020), sepsis meta-analysis 41% mortality reduction
- Metabolic Synergy Research
- In-Vitro Receptor Profiling
- HPLC Verified (≥98% Purity)
Ships same-day if ordered before 2PM EST
Research Overview
Thymosin Alpha-1 (Tα1; also referenced as thymalfasin in portions of the literature) is a 28-amino-acid peptide originally characterized from thymic peptide fractions and widely used as a laboratory reagent in experimental immunology and cell signaling research. Published studies include in vitro cellular systems and in vivo animal models that evaluate Tα1-driven modulation of pattern-recognition receptor signaling, antigen-presenting cell maturation, cytokine network behavior, and downstream transcriptional programs.
Within research settings, Tα1 is commonly studied for its effects on innate/adaptive signaling crosstalk, dendritic cell functional state, T-cell polarization dynamics, and pathway-level biomarkers measured under controlled experimental conditions.